Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aptose Bioscns (NQ: APTO ) 0.3978 UNCHANGED Streaming Delayed Price Updated: 3:56 PM EST, Nov 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Aptose Bioscns < Previous 1 2 3 4 5 Next > Aptose Announces Results from Special Meeting of Shareholders September 05, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Why Zhibao Technology Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket September 03, 2024 Via Benzinga Hello Group, Zscaler And 3 Stocks To Watch Heading Into Tuesday September 03, 2024 Via Benzinga Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib August 30, 2024 Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients From Aptose Biosciences, Inc. Via GlobeNewswire Recap: Aptose Biosciences Q4 Earnings March 26, 2024 Via Benzinga Aptose Announces Adjournment of its Special Meeting of Shareholders August 15, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire APTO Stock Earnings: Aptose Biosciences Beats EPS for Q2 2024 August 09, 2024 APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Aptose Reports Results for the Second Quarter 2024 August 08, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Receipt of Deficiency Notice from Nasdaq July 19, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Biosciences's Earnings: A Preview March 25, 2024 Via Benzinga Aptose Announces Results from Annual and Special Meeting of Shareholders June 18, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress June 14, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules June 03, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules May 31, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire APTO Stock Earnings: Aptose Biosciences Beats EPS for Q1 2024 May 14, 2024 APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Aptose Reports Results for the First Quarter 2024 May 14, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024 May 06, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire APTO Stock Earnings: Aptose Biosciences Beats EPS for Q4 2023 March 26, 2024 APTO stock results show that Aptose Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Aptose Reports Results for the Fourth Quarter and Full Year 2023 March 26, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024 March 18, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Earnings Scheduled For March 26, 2024 March 26, 2024 Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million. Via Benzinga Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option January 31, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Levi Strauss Layoffs 2024: What to Know About the Latest LEVI Job Cuts January 26, 2024 Levi Strauss layoffs are coming for as much as 15% of its corporate workforce as it prepares for a rough economy in 2024! Via InvestorPlace Topics Economy Workforce Exposures Economy Layoff Why Is SU Group (SUGP) Stock Moving Today? January 26, 2024 SU Group stock volatile on Friday following the company's IPO earlier this week with shares currently trading below its debut price. Via InvestorPlace Topics Initial Public Offering Exposures Securities Market Why Is Aptose Biosciences (APTO) Stock Down Today? January 26, 2024 Aptose Biosciences stock is sliding lower on Friday as investors react to a public offering and private placement for APTO shares. Via InvestorPlace Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical January 26, 2024 From Aptose Biosciences, Inc. Via GlobeNewswire Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket January 26, 2024 Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% to... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday January 26, 2024 Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning! Via InvestorPlace Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting December 09, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role November 30, 2023 From Aptose Biosciences, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
